阿司匹林在肝癌防治中的应用进展与争议

巴桃桃; 肖鹏; 丁梦梦; 高沿航

doi:10.3969/j.issn.1001-5256.2020.08.037

阿司匹林在肝癌防治中的应用进展与争议

DOI: 10.3969/j.issn.1001-5256.2020.08.037

吉林大学第一医院肝胆胰内科

基金项目:

国家自然科学基金资助项目(81972265)；国家重点研发计划“精准医学研究”专项(2017YFC0908103)； “艾滋病和病毒性肝炎等重大传染病防治”国家科技重大专项(2017ZX10202202,2018ZX10302206)；吉林大学白求恩计划项目(2018B32);吉林大学高层次创新团队建设项目(2017TD-08)；中央高校基本科研业务费专项资金；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 581
- HTML全文浏览量: 11
- PDF下载量: 170
- 被引次数: 0
出版历程
- 出版日期: 2020-08-20

Application of aspirin in the prevention and treatment of liver cancer:Research advances and controversies

Department of Hepatology, The First Hospital of Jilin University

Research funding:

摘要

摘要:
肝癌的治疗在近年取得了长足的进步。炎症在肝癌发生发展中扮演了重要角色,而阿司匹林可发挥抗炎作用。基础及临床研究发现,阿司匹林可抑制肝癌的发生发展,并辅助应用于肝癌综合治疗,协同其他药物发挥抗癌效应。阿司匹林成本低且易获取,因其在肝癌辅助治疗领域的潜力而引人注目,但在临床实践应用中仍存在诸多问题与困惑。对近年来阿司匹林在肝癌防治中的研究进展、现阶段面临问题及未来发展方向等进行总结及评述,以增加这一领域的认识及积累,为未来真实世界的临床应用奠定基础。
- 肝肿瘤 /
- 阿司匹林 /
- 治疗学
Abstract:
Great achievements have been made in the treatment of liver cancer in recent years.Inflammation plays an important role in the development and progression of liver cancer,while aspirin can exert an anti-inflammatory effect.Basic and clinical studies have found that aspirin can inhibit the development and progression of liver cancer,assist in the comprehensive treatment of liver cancer,and exert an anticancer effect together with other drugs.Aspirin has low costs and is easy to access,and its potential in the adjuvant therapy for liver cancer has attracted great attention;however,there are still many problems and confusions in the application of aspirin in clinical practice.This article summarizes and reviews the recent research advances in aspirin in the prevention and treatment of liver cancer,the problems faced at present,and the future development direction,in order to improve the understanding of this field and lay a foundation for clinical application in the real world in the future.
- liver neoplasms /
- aspirin /
- therapeutics

HTML全文

参考文献(31)

[1] HONG JT,SON DJ,LEE CK,et al. Interleukin 32,inflammation and cancer[J]. Pharmacol Ther,2017,174:127-137.

[2] WANG G,WANG Q,HUANG Q,et al. Upregulation of mt SSB by interleukin-6 promotes cell growth through mitochondrial biogenesis-mediated telomerase activation in colorectal cancer[J]. Int J Cancer,2019,144(10):2516-2528.

[3] ZHONG Z,SANCHEZ-LOPEZ E,KARIN M. Autophagy,inflammation,and immunity:A troika governing cancer and its treatment[J]. Cell,2016,166(2):288-298.

[4] YANG YM,KIM SY,SEKI E. Inflammation and liver cancer:Molecular mechanisms and therapeutic targets[J]. Semin Liver Dis,2019,39(1):26-42.

[5] THUN MJ,NAMBOODIRI MM,HEATH CW Jr. Aspirin use and reduced risk of fatal colon cancer[J]. N Engl J Med,1991,325(23):1593-1596.

[6] SAUER CM,MYRAN DT,COSTENTIN CE,et al. Effect of long term aspirin use on the incidence of prostate cancer:A systematic review and meta-analysis[J]. Crit Rev Oncol Hematol,2018,132:66-75.

[7] TSOI K,HO J,CHAN F,et al. Long-term use of low-dose aspirin for cancer prevention:A 10-year population cohort study in Hong Kong[J]. Int J Cancer,2019,145(1):267-273.

[8] QIAO Y,YANG T,GAN Y,et al. Associations between aspirin use and the risk of cancers:A meta-analysis of observational studies[J]. BMC Cancer,2018,18(1):288.

[9] TANG LP,TANG CW,WANG CH,et al. Inhibiting effects of aspirin on the growth of human hepatocellular carcinoma[J].Chin J Hepatol,2002,10(4):290-293.(in Chinese)汤丽萍，唐承薇，王春晖，等．阿司匹林抑制肝癌生长的试验研究[J]．中华肝脏病杂志，2002,10(4):290-293.

[10] SIMON TG,MA Y,LUDVIGSSON JF,et al. Association between aspirin use and risk of hepatocellular carcinoma[J].JAMA Oncol,2018,4(12):1683-1690.

[11] TAO Y,LI Y,LIU X,et al. Nonsteroidal anti-inflammatory drugs,especially aspirin,are linked to lower risk and better survival of hepatocellular carcinoma:A meta-analysis[J].Cancer Manag Res,2018,10:2695-2709.

[12] SAHASRABUDDHE VV,GUNJA MZ,GRAUBARD BI,et al.Nonsteroidal anti-inflammatory drug use,chronic liver disease,and hepatocellular carcinoma[J]. J Natl Cancer Inst,2012,104(23):1808-1814.

[13] LEE TY,HSU YC,TSENG HC,et al. Association of daily aspirin therapy with risk of hepatocellular carcinoma in patients with chronic hepatitis B[J]. JAMA Intern Med,2019,179(5):633-640.

[14] HWANG IC,CHANG J,KIM K,et al. Aspirin use and risk of hepatocellular carcinoma in a national cohort study of Korean adults[J]. Sci Rep,2018,8(1):4968.

[15] LEE M,CHUNG GE,LEE JH,et al. Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment[J]. Hepatology,2017,66(5):1556-1569.

[16] CHEN H,CAI W,CHU E,et al. Hepatic cyclooxygenase-2overexpression induced spontaneous hepatocellular carcinoma formation in mice[J]. Oncogene,2017,36(31):4415-4426.

[17] MARTN-SANZ P,CASADO M,BOSCL. Cyclooxygenase2 in liver dysfunction and carcinogenesis:Facts and perspectives[J]. World J Gastroenterol,2017,23(20):3572-3580.

[18] YANG G,WANG Y,FENG J,et al. Aspirin suppresses the abnormal lipid metabolism in liver cancer cells via disrupting an NFκB-ACSL1 signaling[J]. Biochem Biophys Res Commun,2017,486(3):827-832.

[19] LIU YX,FENG JY,SUN MM,et al. Aspirin inhibits the proliferation of hepatoma cells through controlling GLUT1-mediated glucose metabolism[J]. Acta Pharmacol Sin,2019,40(1):122-132.

[20] YANG G,WANG Y,FENG J,et al. Aspirin suppresses the abnormal lipid metabolism in liver cancer cells via disrupting an NFκB-ACSL1 signaling[J]. Biochem Biophys Res Commun,2017,486(3):827-832.

[21] RAZA H,JOHN A,BENEDICT S. Acetylsalicylic acid-induced oxidative stress,cell cycle arrest,apoptosis and mitochondrial dysfunction in human hepatoma HepG2 cells[J].Eur J Pharmacol,2011,668(1-2):15-24.

[22] HUANG Z,FANG W,LIU W,et al. Aspirin induces Beclin-1-dependent autophagy of human hepatocellular carcinoma cell[J]. Eur J Pharmacol,2018,823:58-64.

[23] GU H,BAI CC,LIU L,et al. Research advances in traditional Chinese medicine regulation of autophagy in treatment of liver cancer[J]. J Clin Hepatol,2019,35(11):2582-2587.(in Chinese)顾欢，白长川，刘柳，等．中医药调控自噬治疗肝癌的研究现状[J]．临床肝胆病杂志，2019,35(11):2582-2587.

[24] SUN D,LIU H,DAI X,et al. Aspirin disrupts the m TOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via m TORC1 inhibition[J]. Cancer Lett,2017,406:105-115.

[25] LI JH,WANG Y,XIE XY,et al. Aspirin in combination with TACE in treatment of unresectable HCC:A matched-pairs analysis[J]. Am J Cancer Res,2016,6(9):2109-2116.

[26] LI S,DAI W,MO W,et al. By inhibiting PFKFB3,aspirin overcomes sorafenib resistance in hepatocellular carcinoma[J].Int J Cancer,2017,141(12):2571-2584.

[27] XIA H,LEE KW,CHEN J,et al. Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib[J]. Cell Death Discov,2017,3:17058.

[28] MIAO R,XU X,WANG Z,et al. Synergistic effect of nutlin-3combined with aspirin in hepatocellular carcinoma HepG2 cells through activation of Bcl-2/Bax signaling pathway[J]. Mol Med Rep,2018,17(3):3735-3743.

[29] ABDLMONSIF DA,SULTAN AS,EL-HADIDY WF,et al. Targeting AMPK,m TOR andβ-catenin by combined metformin and aspirin therapy in HCC:An appraisal in Egyptian HCC patients[J]. Mol Diagn Ther,2018,22(1):115-127.

[30] XIE ZY,LIU MS,ZHANG C,et al. Aspirin enhances the sensitivity of hepatocellular carcinoma side population cells to doxorubicin via miR-491/ABCG2[J]. Biosci Rep,2018,38(6):BSR20180854.

[31] SITIA G,AIOLFI R,DI LUCIA P,et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B[J]. Proc Natl Acad Sci U S A,2012,109(32):e2165-e2172.

施引文献

资源附件(0)

访问统计